<DOC>
	<DOCNO>NCT02157636</DOCNO>
	<brief_summary>Open-label , sequential dose escalation expansion study CPI-0610 patient previously treat multiple myeloma . CPI-0610 small molecule inhibitor bromodomain extra-terminal ( BET ) proteins .</brief_summary>
	<brief_title>A Phase 1 Study Evaluating CPI-0610 Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Adults ( age ≥ 18 year ) Histologically cytologically confirm diagnosis multiple myeloma progress despite least one line standard therapy Must measurable disease , define one following : ( ) serum M protein &gt; 0.5 g/dl measure serum protein electrophoresis ; ( ii ) urinary M protein excretion &gt; 200 mg/24 hour ; ( iii ) serum free light chain ( FLC ) measurement &gt; 10 mg/dl , provide serum FLC ratio abnormal Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Adequate hematological , renal , hepatic , coagulation laboratory assessment Written inform consent participate study performance studyrelated procedure Current infection HIV , Hepatitis B Hepatitis C Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption CPI0610 , include unresolved nausea , vomit , diarrhea CTCAE grade &gt; 1 Impaired cardiac function clinically significant cardiac disease , include follow : Acute myocardial infarction angina pectoris ≤ 6 month prior start study drug Serum cardiac troponin ( cTn ) level ≥ 99 % percentile upper reference limit QTcF &gt; 470 msec screen ECG Left ventricular ejection fraction ( LVEF ) &lt; 50 % Uncontrolled cardiac arrhythmia ( patient ratecontrolled atrial fibrillation exclude . ) Any concurrent severe and/or uncontrolled concomitant medical condition could compromise participation study ( e.g. , clinically significant pulmonary disease , clinically significant neurological disorder , active uncontrolled infection ) Systemic anticancer treatment radiotherapy le 2 week first dose CPI0610 Treatment investigational small molecule le 2 week first dose CPI0610 . In addition , first dose CPI0610 occur period equal great 5 halflives small molecule investigational agent elapse Treatment therapeutic antibody le 4 week first dose CPI0610 . A minimum 2week period last treatment therapeutic antibody first dose CPI0610 may permit patient rapidly progressive myeloma , follow discussion medical monitor Treatment medication know strong inhibitor inducer CYP450 enzymes Treatment medication know carry risk Torsades de Pointes Immunosuppressive treatment discontinue prior study entry duration study . Oral prednisone dose 10 mg less per day allow , oral corticosteroid give glucocorticoidequivalent dos . Topical , nasal inhaled corticosteroid also allow Pregnant lactate woman Women childbearing potential men reproductive potential , unwilling use adequate contraception study therapy 3 month thereafter Patients unwilling unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Oncology</keyword>
	<keyword>BET Inhibitor</keyword>
</DOC>